New BioIVT Research on Botanical-Drug Interactions Published in Applied In Vitro Toxicology
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that its ADME-Tox team has co-authored a second peer-reviewed paper investigating the potential for clinically-relevant botanical-drug interactions (BDIs) with toxicology colleagues at The Procter & Gamble Company (P&G).1 The paper describes a research collaboration by BioIVT and P&G based on studies conducted in BioIVT’s laboratory in Durham, NC.Read more
BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.Read more
Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be co-hosting a one-hour webinar entitled “Gaining Clarity: Unique Considerations for the Ethical and Regulatory Use of Human Biospecimens in the European Union (EU) and United Kingdom (UK)” at 8 a.m. EST on Mar. 19.
BioIVT Launches Its XPRESSWAY® Profile Safety Package, a Gene Expression Reference Guide Designed to Improve Drug Safety Analyses
This new product will help pharmaceutical companies to assess drug safety risks, inform go/no-go decisions in lead selection, and expedite drug discovery programs.
BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity
Acquisition increases BioIVT’s supply of leukopaks, plasma, and sera, and enhances its ability to support the in vitro diagnostic market.
BioIVT Appoints Alan Findlater as Chief Commercial Officer
BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services.
BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services
QMS, Master Control will help to ensure consistent document tracking and training across all BioIVT sites and support the company’s rapid growth
Acquiring this donor center and laboratory will enable BioIVT to ship high-quality blood products and blood-derived immune cells efficiently to researchers throughout Europe
BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also has full-service cell processing capabilities on site.
HEPATOPAC bioengineered micro-liver platforms are widely used for drug efficacy and safety research.
BioIVT, a leading provider of research models and services for drug development, today announced that it will be hosting the 2018 HEPATOPAC User Group Meeting (UGM) from 8:30 a.m. to 4:30 p.m. ET on Oct. 18 in Boston, MA.
The C-DILI™ Assay is a highly effective tool for assessing cholestatic hepatotoxicity risk of promising new drug candidates.
BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.